and the few results] to use this drug from tonight on, if necessary!

Hope that Pfizer will not “block [corrupt this] this” with their capital” and that our Government will get siyata dishmaya to approve this stante pede.

If you can influence anyone in this process then please ACT!

Hospital seeks emergency approval of Israeli COVID drug for moderate-seriously ill

In letter to Health Ministry director, Ziv Medical Center points to promising results from Amor 18’s clinical trial, where all patients who received drug went on to recover

By TOI STAFFToday, 12:39 am  

Medical workers operate in the coronavirus ward of Ziv Medical Center on September 22, 2021. (David Cohen/Flash90)

Safed’s Ziv Medical Center has sent a letter to Health Ministry director Nachman Ash requesting he grant emergency authorization for the anti-COVID drug Amor 18 developed by the Israeli company Amorphical in order to treat patients in moderate to serious condition due to the coronavirus, Channel 2 reported Friday.

Israeli biotech company Amorphical recently published what it says are promising results from the second stage of its Amor 18 clinical study.

In the first stage conducted at Ziv, Be’er Yaakov’s Assaf Harofeh and Tel Aviv’s Ichilov Hospital all patients who received the drug, which is either inhaled or taken under the tongue, went on to recover from COVID-19 and were released from the hospital

In the second phase of the trial, Ziv Medical Center recruited 37 patients in moderate-to-severe conditions to participate. Eighteen of them were given Amor 18 and 19 received a placebo.

All the patients who received Amor 18 recovered and were discharged several days later. Of the 19 others, six of them saw their condition deteriorate and had to be transferred to the ICU. Two of those patients died.Get The Times of Israel’s Daily Editionby email and never miss our top storiesNewsletter email addressGET ITBy signing up, you agree to the terms

Dr. Nashat Abu Saleh, who heads the geriatrics department at Ziv Medical Center told Ash in the letter that two patients in critical condition who didn’t qualify for the trial were also given Amor 18 through compassionate use. Both of them saw their subsequent conditions significantly improve and were later released from the hospital.Hospital staff wearing safety gear as they work in the coronavirus ward of Ziv Medical Center in the northern Israeli city of Tzfat on February 4, 2021. (David Cohen/Flash90)

If granted, the emergency authorization would be rather rare as Israeli health authorities typically rely on the US Food and Drug Administration approvals for such drugs.

But doctors at Ziv were confident that Amor 18 warranted a special, fast-tracked Israeli approval.ADVERTISEMENT

“In light of the unequivocal results in terms of safety and efficacy, and in light of the spread of the fifth wave — we would be grateful to receive an emergency permit to administer the drug to all coronavirus patients who are hospitalized with us,” Abu Saleh wrote to Ash.

The Amor 18 trial is expected to expand soon to medical centers in the United States and Europe and is awaiting approval from the Brazilian Drug Administration (ANVISA).